
    
      This study is a randomized, open-label, 2-way crossover study to assess pharmacodyamic and
      pharmacokinetic profiles following treatment with PL-ASA and EC-ASA administered under
      fasting condition at a single dose of 81 mg among the volunteers aged 50 to 75 years.
    
  